HLB Group announced on Friday that it will present the latest research findings from its major anti-cancer pipelines at the American Association for Cancer Research Annual Meeting (AACR 2026) next month in San Diego, California.
The AACR is recognized as one of the world’s top three cancer conferences, alongside the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO).
Verismo Therapeutics, a U.S. subsidiary of HLB Innovation, will unveil interim results from its Phase 1 clinical trial of the chimeric antigen receptor T-cell (CAR-T) therapy SynKIR-110 for solid tumors at this year’s AACR. This marks the first public release of actual clinical data.
SynKIR-110, developed using Verismo’s proprietary KIR-CAR technology, has garnered significant attention for its potential to overcome T-cell exhaustion – a common issue with existing CAR-T therapies caused by excessive T-cell activation. Consequently, there is heightened interest in its safety and efficacy data.
HLB’s subsidiary, Elevar Therapeutics, will also present an analysis comparing the Fibroblast Growth Factor Receptor 2 (FGFR2) selectivity of its FGFR2-targeted cancer drug Lirafugratinib with existing pan-FGFR inhibitors.
Lirafugratinib showcased its potential as a best-in-class treatment by demonstrating efficacy and safety through global Phase 2 clinical data presented at the ASCO Gastrointestinal (GI) 2026 symposium in January.
Designated as an innovative therapy in 2023, Lirapegutrinib’s application for the U.S. Food and Drug Administration (FDA) approval was completed in January based on the Phase 2 results. The company anticipates that the additional analysis results to be presented at AACR will provide compelling evidence to highlight Lirafugratinib’s unique advantages during the commercialization process.
Nam Kyung-sook, Executive Director of HLB Group’s Bio Strategy Planning Team, stated that this AACR presentation offers an opportunity to clearly demonstrate the technological differentiation and clinical value of HLB Group’s next-generation anti-cancer pipeline to the global market.